Point of Care OGTT for the screening of Gestational Diabetes: a feasible proposal for low resource settings

Dr Héctor Gallardo Rincón\textsuperscript{a}, Dr Julieta Lomelín Gascon\textsuperscript{a}, Dr Luis Alberto Martinez Juarez\textsuperscript{b}, DSc Airaín Alejandra Montoya Rodríguez\textsuperscript{a}, Dr Enrique Reyes Muñoz\textsuperscript{c}, Dr Roberto Tapia-Conyer\textsuperscript{a}.

\textbf{Affiliations:}
\textsuperscript{a}Carlos Slim Foundation
\textsuperscript{b}Mexican Society of Public Health
\textsuperscript{c}National Institute of Perinatology (Mexico)

Project funded by Global Health Partnership Eli Lilly & Company

Abstract: 1358-P
**FINANCIAL DISCLOSURE**

**Presenter:** Dr Luis Alberto Martinez Juarez\(^b\)

Dr Martinez declares to be working in a project funded by Global Health Partnership Eli Lilly & Company

**Co-authors:**
Dr Héctor Gallardo Rincón\(^a\)
Dr Julieta Lomelín Gascon\(^a\)
DSc Airaín Alejandra Montoya Rodríguez\(^a\)
Dr Enrique Reyes Muñoz\(^c\)
Dr Roberto Tapia-Conyer\(^a\)

**Affiliations:**
\(^a\) Carlos Slim Foundation  
\(^b\) Mexican Society of Public Health  
\(^c\) National Institute of Perinatology (Mexico)

Drs Gallardo, Lomelin, Montoya, Reyes, and Tapia-Conyer have no conflicts of interest
Rationale

The global prevalence of Gestational Diabetes Mellitus (GDM) is estimated to be between 7.5 and 27% \(^1\).

The information available in Mexico is not sufficient to measure the national prevalence of GDM, however it is estimated that it varies between 10 and 12% \(^2,3\).

Screening and diagnostic strategies have been the subject of international debate. At this time the oral glucose tolerance test (OGTT) is considered the Gold Standard for the diagnosis of GDM.

The American Diabetes Association (ADA) recommends three venous plasma glucose samples (fasting, 1 h and 2h after the intake of 75g of glucose)\(^4\). This criteria has been recommended for the diagnosis of DMG in Mexico \(^2,5\).

However, it is difficult to perform the GDM screening in many low-resource settings due to limited access to standardized laboratories.

Objective

To compare the efficacy of two point of care (POC) models for GDM detection against the plasmatic 2hr OGTT-75gr in primary health care clinics in Mexico.
We evaluated 328 pregnant women without a previous diagnosis of diabetes from a prospective cohort study 'Cuido mi embarazo'.

All participants were tested with the gold standard plasmatic 2hr OGTT-75g for the diagnosis of GDM between the 24th and 28th weeks of pregnancy.

The diagnosis was made based on the criteria of the ADA 2020, which is the same diagnostic criteria recommended by Mexican guidelines.

Simultaneously, we measured with a glucometer (Accu-Chek Instant®) the glucose concentration either by venous whole blood (156 measures) or by capillary whole blood (172 measures).

We evaluated the diagnostic accuracy by calculating the sensitivity, specificity, and area under the Curve (AUD) of ROC curve of each of the glucometer models compared to the 2hr OGTT-75g (Gold Standard).
RESULTS

Model 1 (Venous blood analyzed by glucometer)

Table 1. AUC of ROC curve, sensitivity and specificity of Model 1 with respect to the Gold Standard

<table>
<thead>
<tr>
<th>Analysis of model 1</th>
<th>AUC of ROC curve (95% CI)</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.81 (0.77-0.85)</td>
<td>100%</td>
<td>62.8%</td>
</tr>
</tbody>
</table>

Table 2. Pearson correlation coefficient, AUC of ROC curve, sensitivity and specificity by each glucose measurements with respect to the Gold Standard

<table>
<thead>
<tr>
<th>OGTTC Measurement</th>
<th>Pearson correlation coefficient</th>
<th>P value</th>
<th>AUC of ROC curve (95% CI)</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting value</td>
<td>0.62</td>
<td>&lt; 0.05</td>
<td>0.81 (0.77-0.85)</td>
<td>100%</td>
<td>63.5%</td>
</tr>
<tr>
<td>Value 1 hr.</td>
<td>0.94</td>
<td></td>
<td>0.97 (0.95-0.99)</td>
<td>100%</td>
<td>95.2%</td>
</tr>
<tr>
<td>Value 2 hr.</td>
<td>0.93</td>
<td></td>
<td>0.98 (0.97-0.99)</td>
<td>100%</td>
<td>97.3%</td>
</tr>
</tbody>
</table>

Figure 1. AUC of ROC curve of Model 1 and each glucose measurements with respect to the Gold Standard
RESULTS

Model 2 (Capillary blood analyzed by glucometer)

Table 3. AUC of ROC curve, sensitivity and specificity of Model 2 with respect to the Gold Standard

<table>
<thead>
<tr>
<th>Analysis of model 2</th>
<th>AUC of ROC curve (95% CI)</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.76 (0.64-0.87)</td>
<td>78.5%</td>
<td>74.1%</td>
</tr>
</tbody>
</table>

Table 4. Pearson correlation coefficient, AUC of ROC curve, sensitivity and specificity by each glucose measurements with respect to the Gold Standard

<table>
<thead>
<tr>
<th>OGGTT Measurement</th>
<th>Pearson correlation coefficient</th>
<th>P value</th>
<th>AUC of ROC curve (95% CI)</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting value</td>
<td>0.42</td>
<td>&lt; 0.05</td>
<td>0.77 (0.65-0.89)</td>
<td>76.9%</td>
<td>77.9%</td>
</tr>
<tr>
<td>Value 1 hr.</td>
<td>0.56</td>
<td></td>
<td>0.76 (0.52-1.00)</td>
<td>60.0%</td>
<td>93.4%</td>
</tr>
<tr>
<td>Value 2 hr.</td>
<td>0.53</td>
<td></td>
<td>0.72 (0.23-1.00)</td>
<td>50.0%</td>
<td>95.8%</td>
</tr>
</tbody>
</table>

Figure 2. AUC of ROC curve of Model 2 and each glucose measurements with respect to the Gold Standard
CONCLUSION AND DISCUSSION

This analysis conducted within the Cohort ‘Cuido mi Embarazo’ in Mexico aims to analyze alternative strategies for GDM screening.

The models we studied are based on the use of a glucometer. The first model focused on performing the OGTT with venous whole blood without the need to have a laboratory installed. The second model was considered for those situations where it is only possible to have capillary glucose measurements.

Based on our preliminary results, the sensitivity and specificity of both models suggest an opportunity to use alternative methods to the Gold Standard where this test cannot be performed.

In particular, Model 1 (with an AUC of ROC curve of 0.81; 95% CI: 0.77 - 0.85) shows to be a good alternative screening strategy by using the same reference values for the diagnosis of GDM than the Gold Standard.

However, we must consider that the use of capillary blood is operationally easier to use in low-resource settings. It requires less training, is minimally invasive, is portable, is better accepted by the patient and is cost-effective\(^6\). Some studies suggest the consideration of capillary blood glucose as a screening alternative for GDM with adequate sensitivity and specificity\(^7-9\).

This analysis suggests that Model 2 (with an AUC of ROC curve of 0.76; 95% CI: 0.64 - 0.87) has good specificity to be considered as a screening strategy for GDM by using the same reference values than the Gold Standard.

It is necessary to carry out additional sensitivity and specificity studies considering different glucose reference values to increase their respective diagnostic capacity.


